Core Insights - Bespoke Extracts, Inc. reported record results for Q3 2025, achieving its strongest operational and financial performance to date [1] - The company emphasizes disciplined execution and brand trust as key factors for success in a contracting cannabis market [2][3] Financial Performance - Revenue for Q3 2025 reached $467,945, representing a 68.6% increase year-over-year and a 19.8% increase from Q2 2025 [4][6] - Gross profit was $234,175, up 103.6% from Q3 2024, with a gross margin of 50.0%, an increase of 860 basis points year-over-year [4][6] - Operating expenses decreased by 23.7% compared to Q3 2024, leading to a net loss of $78,088, a 71.7% improvement from the previous year [4][6] Production and Market Strategy - The company produced 209,600 pre-rolls in Q3 2025, an 81% increase year-over-year [6] - Bespoke Extracts aims to replicate its successful model across additional regulated markets, including Massachusetts and New York [10] Future Outlook - Projected revenue for Q4 2025 is between $425,000 and $500,000, indicating a year-over-year growth of 41% to 66% [10] - The company plans to launch two new brands in Q4 to capture adjacent market segments [10]

Core Insights - Bespoke Extracts, Inc. reported a significant revenue increase of 48.4% in Q2 2025, reaching $390,553 compared to $263,159 in Q1 2025 and a 40.4% increase from $278,163 in Q2 2024 [2][4] - The company achieved a gross margin of 50.6%, which is an increase of 1,250 basis points year-over-year, reflecting improved operational efficiencies [2][4] - Despite the revenue growth, the company reported a GAAP net loss of $205,106 for Q2 2025, an improvement from a net loss of $260,895 in Q2 2024 [4][6] Financial Highlights - For the three months ended June 30, 2025: - Revenue: $390,553, up 40.4% year-over-year [4] - Gross Profit: $197,499, with a gross profit margin of 50.6% [3][4] - Net Loss: $205,106, resulting in a net loss per share of $0.02 [4][5] - For the six months ended June 30, 2025: - Revenue: $653,712, an increase of 21.4% compared to the same period in 2024 [4] - Gross Profit: $308,278, with a gross profit margin of 47.2% [5] - Net Loss: $465,627, with a net loss per share of $0.04 [5] Operational Highlights - The company produced a record number of over 177,000 pre-rolls in Q2 2025, driven by strong demand for its core Fresh Joints product line and new product lines like Doobskis and Dutch Blunts [6][7] - Continued improvements in manufacturing processes and cost efficiencies in raw materials, packaging, and labor contributed to the gross margin expansion [6][9] - The company is exploring expansion opportunities in other regulated cannabis markets, such as Massachusetts and New York [10] Future Outlook - Preliminary sales data for Q3 2025 indicates continued revenue growth, with projections between $425,000 and $450,000, representing a 53% to 62% increase over Q3 2024 [8] - The company expects further improvements in gross margins due to enhanced production efficiencies and cost management [9]

Core Insights - Bespoke Extracts, Inc. has successfully rebranded as The Joint Company (TJC) and launched new products, Doobskis and Dutch Blunts, which are gaining traction in Colorado's cannabis market [3][5] - Despite an 8.8% contraction in Colorado's regulated cannabis market, the company achieved year-over-year revenue growth [5] - The company is focused on expanding its market share and optimizing operations for sustainable growth [8] Financial Highlights for Q1 2025 - Revenue increased to $263,159, up 1.0% from $260,428 in Q1 2024, driven by strong sales of branded pre-rolled joints [7] - Gross profit rose to $110,779 from $102,581 in Q1 2024, supported by improved production efficiencies [7] - Operating expenses decreased to $356,117 from $405,384 in Q1 2024, reflecting lower stock-based compensation and reduced salaries [7] - Net loss decreased to $260,521 from $314,118 in Q1 2024 [7] Operational Highlights - Daily pre-roll production increased by 32% compared to Q1 2024, enhancing TJC's competitive processing capabilities [8] - The company achieved cost efficiencies in raw materials, packaging, and labor, boosting gross margins despite increased marketing costs [8] - Management is exploring expansion into other state-regulated cannabis markets, leveraging successful operations in Colorado [8] Fiscal Q2 2025 Outlook - Projected revenue for Q2 2025 is expected to exceed $385,000, compared to $278,163 in Q2 2024, driven by strong demand for new product lines [11] - Continued improvements in manufacturing processes are anticipated to support higher production volumes and consistent product quality [11] - Enhanced production efficiencies and cost management are projected to drive higher gross margins [11]